In dementia research, obtaining informed consent presents unique challenges, in part due to participants' cognitive impairments and fluctuating decision-making capacities. Much of the literature on this topic has previously centred on the perspectives of researchers and healthcare professionals, with less focus on individuals with lived experience of dementia. Alzheimer Europe is pleased to have published a perspectives article in the Frontiers in Dementia journal, addressing this gap.
The Executive Board of the World Health Organization (WHO) has adopted a recommendation to extend the Global Action Plan on the Public Health Response to Dementia 2017-2025, which would see it continue until 2031. The 78th World Health Assembly (WHA), at which the final decision will be made, will be held in May of this year.
It is with great pleasure that we introduce the 47th edition of our Dementia in Europe magazine. Following the 34th Alzheimer Europe Conference (34AEC) in Geneva, (Switzerland), it has been a busy period with lots of interesting developments across Europe in relation to policy, research, culture, advocacy and dementia care. Be sure to check out our special supplement to this magazine, also, focusing on our Annual Conference in Geneva.
The European Medicines Agency (EMA) has reaffirmed its positive opinion on lecanemab, after discussions at the February Committee for Medicinal Products for Human Use (CHMP) meeting. The European Commission had asked the CHMP to consider updating its opinion, following new information on the safety of lecanemab, but after the February CHMP meeting the EMA announced that no updates would be required to its opinion.
Alzheimer Europe's 
In dementia research, obtaining informed consent presents unique challenges, in part due to participants' cognitive impairments and fluctuating decision-making capacities. Much of the literature on this topic has previously centred on the perspectives of researchers and healthcare professionals, with less focus on individuals with lived experience of dementia. Alzheimer Europe is pleased to have published a perspectives article in the Frontiers in Dementia journal, addressing this gap.
The Executive Board of the World Health Organization (WHO) has adopted a recommendation to extend the Global Action Plan on the Public Health Response to Dementia 2017-2025, which would see it continue until 2031. The 78th World Health Assembly (WHA), at which the final decision will be made, will be held in May of this year.
It is with great pleasure that we introduce the 47th edition of our Dementia in Europe magazine. Following the 34th Alzheimer Europe Conference (34AEC) in Geneva, (Switzerland), it has been a busy period with lots of interesting developments across Europe in relation to policy, research, culture, advocacy and dementia care. Be sure to check out our special supplement to this magazine, also, focusing on our Annual Conference in Geneva.
The European Medicines Agency (EMA) has reaffirmed its positive opinion on lecanemab, after discussions at the February Committee for Medicinal Products for Human Use (CHMP) meeting. The European Commission had asked the CHMP to consider updating its opinion, following new information on the safety of lecanemab, but after the February CHMP meeting the EMA announced that no updates would be required to its opinion.